Vivek Subbiah: I have accepted the debate at the 2024 AACR Industry Roundtable

Vivek Subbiah shared a post on LinkedIn:

“Breaking news:

Announcing the Debate of the Year! 2024

YES, I have ACCEPTED to debate at the 2024 American Association for Cancer Research
INDUSTRY ROUNDTABLE 2024!

Thanks to the vision of AACR President elect Lillian Siu for this session and thanks for the invitation as speaker for the debate.

Date: October 8th 2024
Location: Hilton Philadelphia

TOPIC: The integration of early cancer detection and AI-driven technologies will become standard practice in oncology and increase cancer cure rates by 2034.

Moderated by the amazing Lecia Sequist, Massachusetts General Hospital, Harvard Medical School.

Enthusiast: YES!
– Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute Sarah Cannon Research Institute

Realist: NO!
– Alexander T. Pearson, Director of the Center for Computational Medicine and Clinical Artificial Intelligence, Director of Head/Neck Cancer, Associate Professor of Medicine, University of Chicago.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.